Search company, investor...
Ultraspect company logo



Other Investors | Alive

About Ultraspect

ULTRASPECT specializes in the development, production and sale of products dedicated to the enhancement of imaging quality and productivity performance of NM Gamma Cameras. Based on its , reconstruction algorithms technology, Wide-Beam Reconstruction (WBRTM), the company's imaging solutions shorten acquisition times and increase image resolution.

Headquarters Location


Missing: Ultraspect's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ultraspect's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Ultraspect Patents

Ultraspect has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Medical imaging, Medical physics, Radiopharmaceuticals, Sensors, Neuroimaging


Application Date


Grant Date



Related Topics

Medical imaging, Medical physics, Radiopharmaceuticals, Sensors, Neuroimaging



Latest Ultraspect News

UltraSPECT's New Ultra-Secured Gateway Delivers Impenetrable Defense Against Cybercriminals Seeking to Breach Nuke Med Systems

Dec 7, 2017

Military-grade 'USG' gateway ensures airtight data security for users of UltraSPECT's popular image-reconstruction solution AUBURNDALE, MA--(Marketwired - December 07, 2017) - UltraSPECT Inc., a leading provider of image reconstruction solutions supporting safer and faster nuclear cardiology and oncology exams, today announced the availability of a new add-on capability that vigorously protects nuclear imaging operations against every manner of breach, from basic malware to advanced persistent threats posed by the most determined hackers and cybercriminals. UltraSPECT will offer the add-on-called Ultra-Secured Gateway, or USG-with all new installations of its hardware/software platform, UltraSPECT.gate. The company will also offer an upgrade to current users of the platform, which employs its proprietary and innovative Wide-Beam Reconstruction (WBR™) algorithms to markedly improve the clarity of molecular-imaging exams while significantly reducing radiation dose to patients. To develop the USG technology, UltraSPECT partnered with a top cybersecurity firm in Israel and closely followed recommendations as well as regulations propounded by the National Institute of Standards and Technology and the U.S. Department of Defense. In preparing USG for the market, UltraSPECT's product-development team rigorously tested and validated all relevant components. The team performed all Security Content Automation Protocol (SCAP) validations called for by the National Vulnerability Database, hardening and securing both operating system codes and software applications used to run UltraSPECT's Xpress.Cardiac , Xpress3.Cardiac and Xpress/Xact.Bone image-reconstruction products. Further, they implemented the most advanced whitelist security methods available and integrated McAfee application control software. "At UltraSPECT we are well aware of the sharp rise in cyberattacks on healthcare IT networks in general and particularly on sensitive medical equipment," said Yossi Srour, UltraSPECT president and CEO, upon announcing the availability of USG. "We are committed to ensuring our customers' confidence in our products to be not only clinically outstanding and operationally efficient but also impenetrably secure." Srour is not overstating the threat. A 2016 study by the Ponemon Institute showed nearly three-quarters of malware attacks on healthcare organizations involve ransomware. The study also showed the average cost of a security breach is $3.7 million, the average number of days it takes to detect a breach is 146 days-and the average time it takes for a phishing email to be clicked is just 82 seconds after it's sent. "In healthcare, we have to be constantly mindful of how sensitive patients' personal data is-and how much damage can be done to people's lives, not to mention providers' budgets, if that information falls into the wrong hands," said Don Widener, UltraSPECT's vice president of sales. "At the same time, healthcare professionals need fast access to both that very data and the digital tools that help them do their jobs to the best of their ability. We never lost sight of what's at stake for all affected parties as we were developing USG for our existing and future customers." UltraSPECT has been providing image reconstruction solutions supporting safer and faster nuclear cardiology and oncology exams since 2006. It has 550 installations supporting more than 800 SPECT cameras across the U.S., including known luminary university hospitals and Healthcare facilities throughout the state. For more information about the UltraSPECT technologies and reducing dose in nuclear medicine, visit or call 1-888-WBR-SCAN (1-888-927-7226). About UltraSPECT UltraSPECT Inc. is the only provider of image reconstruction solutions that support safer and faster nuclear medicine imaging with the ability for better diagnostic capabilities and higher diagnostic confidence. Based on proprietary, innovative Wide-Beam Reconstruction (WBR™) algorithms, UltraSPECT products continue to be the most cost-effective dose-reduction solutions available to simultaneously lower radiation dose, shorten acquisition times and increase diagnostic quality. Healthcare facilities of all sizes maximize value from the ability to leverage the investment in existing nuclear medicine cameras - regardless of the manufacturer, model and age. Moreover, UltraSPECT solutions enable healthcare facilities to meet the American Society of Nuclear Cardiology (ASNC) low-dose guidelines. UltraSPECT image reconstruction products are approved by the FDA, as well as numerous regulatory authorities in hundreds of leading nuclear medicine imaging centers around the world. For more information, visit . Contact Information

Ultraspect Frequently Asked Questions (FAQ)

  • What is Ultraspect's latest funding round?

    Ultraspect's latest funding round is Other Investors.

  • Who are the investors of Ultraspect?

    Investors of Ultraspect include Giza Venture Capital and Veritas Venture Partners.

  • Who are Ultraspect's competitors?

    Competitors of Ultraspect include Optovue, Redlen Technologies, Capso Vision, Orthoscan, Digirad and 12 more.

Compare Ultraspect to Competitors

Gamma Medica-Ideas

Gamma Medica Ideas, Inc. engages in designing, building, selling, and servicing pre-clinical and clinical imaging systems.

Mirabilis Medical

Mirabilis Medica is in clinical development of a non-invasive therapeutic ultrasound platform with an initial application to the treatment of uterine fibroids. The Mirabilis platform uses high resolution ultrasound imaging to localize treatment, and an ultrasound technology to quickly and non-invasively treat tissue deep in the body.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.


QuantomiX develops products for rapid, high resolution imaging of wet samples.The company was founded in 2001 to commercialize its technology which, for a time, aims to enable direct imaging of fully hydrated samples in an electron microscope.With the Quantomix QXTM capsule product line, wet samples, including cells and tissues, can now be examined without any of the conventional treatments such as drying, deep freezing and sectioning. This opens the way to a better understanding of biomedical processes, to improved patient care, and to more effective pharmaceutical research.The QXTM capsules, that fit any Scanning Electron Microscope (SEM), close the resolution gap between conventional electron microscopy and light microscopy. They offer the convenient sample preparation of light microscopy.

Gendex Corporation

Engages in the research and development, production and distribution of imaging equipment for the dental market. Gendex offers radiology and imaging products, including panoramic x-ray, intraoral x-ray, digital imaging, cameras and software.

Imorphics Limited

Imorphics is a spin-out from the Division of Imaging Science and Biomedical Engineering in the Faculty of Medicine and is based on more than 20 year's research led by Professor Chris Taylor. The company sells 3D medical image analysis software which is being used to improve the speed and accuracy of measurements taken in drug trials. MTF introduced Chairman Mike Bowes to the company. Mike Bowes was previously CEO of Kestra, an imaging start-up backed by 3i which was sold in 1999.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.